“…22,24,26,[30][31][32] This reluctance appears to be driven by the potential for side effects, 33 scant high-quality scientific data, 22,34 unclear dosage guidelines, 17,26 and a lack of regulatory oversight by the FDA, unlike other therapeutic and supportive care drugs. 35 Such concerns are magnified when pediatric clinicians must consider MM use by children and adolescents, particularly because habitual marijuana use is associated with dependence, impaired neurocognitive development, and poor academic achievement in children. 12,15,36,37 Recommending MM may thus be fundamentally problematic for physicians who are accustomed to evidence-based practice, as they cannot be assured by empirical data that benefits outweigh possible harm.…”